VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
Top Cited Papers
- 1 October 2003
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 4 (4) , 263-275
- https://doi.org/10.1016/s1535-6108(03)00241-1
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Ability of the Matrix Protein of Vesicular Stomatitis Virus To Suppress Beta Interferon Gene Expression Is Genetically Correlated with the Inhibition of Host RNA and Protein SynthesisJournal of Virology, 2003
- Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcriptionJournal of Molecular Biology, 2002
- Toward a New Generation of Conditionally Replicating Adenoviruses: Pairing Tumor Selectivity with Maximal OncolysisHuman Gene Therapy, 2002
- Whence Interferon? Variety in the Production of Interferon in Response to Viral InfectionThe Journal of Experimental Medicine, 2002
- Oncolytic biotherapy: a novel therapeutic platformThe Lancet Oncology, 2002
- Gene Induction Pathways Mediated by Distinct IRFs during Viral InfectionBiochemical and Biophysical Research Communications, 2001
- Inhibition of Host Transcription by Vesicular Stomatitis Virus Involves a Novel Mechanism That Is Independent of Phosphorylation of TATA-Binding Protein (TBP) or Association of TBP with TBP-Associated Factor SubunitsJournal of Virology, 2001
- Vesicular Stomatitis Virus (VSV) Therapy of TumorsIUBMB Life, 2000
- Involvement of the IRF family transcription factor IRF‐3 in virus‐induced activation of the IFN‐β geneFEBS Letters, 1998
- Intra-rectal injection of tumour cells: a novel animal model of rectal cancerSurgical Oncology, 1992